PharmTech Drug Digest 11.20
News|Articles|September 22, 2015

Novo to Build Prefilled Insulin Pen Facility in Iran

Novo Nordisk will build a local manufacturing plant for FlexPen prefilled insulin delivery devices in Iran.

Novo Nordisk Iran and the Food and Drug Administration of the Islamic Republic of Iran have signed a Memorandum of Understanding committing Novo Nordisk to build a local manufacturing plant for FlexPen prefilled insulin delivery devices in Iran, the company announced in a Sept. 22, 2015 press release.

The project is expected to last five years and represents a Novo Nordisk investment of approximately 70 million Euros (US$78 million). With construction of the GMP facility, Novo Nordisk will create 160 jobs; Novo Nordisk already employs approximately 130 people in Iran.

"We are happy to commit to this manufacturing facility in Iran. It signals our long-term commitment to Iran, a country where close to five million people have diabetes according to the International Diabetes Federation. This investment will ensure availability of our modern insulins and will bring us a step closer to the people who rely on our products," said Ole Moelskov Bech, corporate vice-president of Novo Nordisk business area Near East, in the release.

Source: Novo Nordisk


Related to this article

white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Green Chemistry Supply and Demand in Sustainable Pharma
Celtic Renewables won the CPHI Award for Sustainable Pharma Excellence for its green chemicals used in pharmaceutical manufacturing. Bettina Brierley, chief commercial officer, talks about the adoption, capacity, and pricing of biosolvents.